You just read:

Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

News provided by

Dauntless Pharmaceuticals, Inc.

16 Feb, 2017, 08:00 ET